TY - JOUR T1 - Salvage Therapy After Regorafenib or Trifluridine/Tipiracil Treatment of Metastatic Colorectal Cancer: A Conditional Landmark Analysis JF - Anticancer Research JO - Anticancer Res SP - 1055 LP - 1062 DO - 10.21873/anticanres.14862 VL - 41 IS - 2 AU - MASAYUKI NAKASHIMA AU - MASATO TAKEUCHI AU - SHIRO TANAKA AU - KOJI KAWAKAMI Y1 - 2021/02/01 UR - http://ar.iiarjournals.org/content/41/2/1055.abstract N2 - Background/aim: This study aimed to describe the chemotherapy effects after trifluridine/tipiracil (TFTD) and/or regorafenib treatment in colorectal cancer (CRC) patients. Patients and Methods: Patients receiving regorafenib or TFTD for metastatic CRC during 2013-2018 were selected and divided into two groups: one with additional chemotherapy after regorafenib or TFTD (CTX group) and one without additional chemotherapy (Non-CTX group). Patients were followed up from a landmark point (90 days from the last day of administration of regorafenib or TFTD). We compared overall survival (OS) between the groups. Results: The median OS was 7.7 months in the CTX group and 4.1 months in the non-CTX groups. Several sensitivity analyses did not negate the survival advantage detected in the CTX group. Conclusion: The chemotherapy after regorafenib or TFTD was associated with prolonged OS in advanced CRC patients. Further study is required to determine appropriate treatment choice. ER -